ARCT | tickerfilter.com

Fundamental analysis

24%

Profitability 25%

Dept financing 10%

Liquidity 69%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

6.78%

1 Month

-5.97%

3 Months

-22.43%

6 Months

-37.08%

1 Year

-47.85%

2 Year

1.47%

Key data

Stock price

$16.50

P/E Ratio

-7.90

DAY RANGE

$17.01 - $20.54

EPS

-$2.70

52 WEEK RANGE

$15.71 - $45.00

52 WEEK CHANGE

-$49.53

MARKET CAP

568.262 M

YIELD

N/A

SHARES OUTSTANDING

26.932 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/12/2024

BETA

1.78

PUBLIC FLOAT

AVERAGE 10 VOLUME

$487,903

AVERAGE 30 VOLUME

$396,548

Company detail

CEO: Joseph E. Payne
Region: US
Website: arcturusrx.com
Employees: 180
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNar-CF program for cystic fibrosis lung disease. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines.

ARCT - Arcturus Therapeutics Holdings Inc.